Development of an ObLiGaRe Doxycycline Inducible Cas9 System for Pre-Clinical Cancer Drug Discovery

The generation of a tightly controlled ObLiGaRe doxycycline inducible SpCas9 (ODInCas9) transgene and its use in targeted ObLiGaRe resulted in functional integration into both human and mouse cells culminating in the generation of the ODInCas9 mouse.
[Nature Communications]
Lundin, A., Porritt, M. J., Jaiswal, H., Seeliger, F., Johansson, C., Bidar, A. W., Badertscher, L., Wimberger, S., Davies, E. J., Hardaker, E., Martins, C. P., James, E., Admyre, T., Taheri-Ghahfarokhi, A., Bradley, J., Schantz, A., Alaeimahabadi, B., Clausen, M., Xu, X., … Maresca, M. (2020). Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery. Nature Communications, 11(1), 4903. https://doi.org/10.1038/s41467-020-18548-9 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Bone Marrow Mesenchymal Stem Cells-Derived Exosomal MicroRNA-193a Reduces Cisplatin Resistance of Non-Small Cell Lung Cancer Cells via Targeting LRRC1

A549 and H1299 cell lines were screened out and their parent cells and drug-resistant cells were co-cultured with human bone marrow mesenchymal stem cells-derived exosomes that had been transfected with miR-193a mimic or si-LRRC1 to detect the colony formation, migration, apoptosis, invasion and proliferation of non-small cell lung cancer cells.
[Cell Death & Disease]
Wu, H., Mu, X., Liu, L., Wu, H., Hu, X., Chen, L., Liu, J., Mu, Y., Yuan, F., Liu, W., & Zhao, Y. (2020). Bone marrow mesenchymal stem cells-derived exosomal microRNA-193a reduces cisplatin resistance of non-small cell lung cancer cells via targeting LRRC1. Cell Death & Disease, 11(9), 1–14. https://doi.org/10.1038/s41419-020-02962-4 Cite
Full Article
Bookmark

No account yet? Register

0
Share

FGFR1 Is Critical for Rbl2 Loss-Driven Tumor Development and Requires PLCG1 Activation for Continued Growth of Small Cell Lung Cancer

Researchers showed that increased fibroblast growth factor receptor 1 (FGFR1) promoted tumorigenic progression in precancerous neuroendocrine cells and is required for small cell lung cancer development in vivo.
[Cancer Research]
Kim, K.-B., Kim, Y., Rivard, C. J., Kim, D.-W., & Park, K.-S. (2020). FGFR1 is critical for Rbl2 loss-driven tumor development and requires PLCG1 activation for continued growth of small cell lung cancer. Cancer Research. https://doi.org/10.1158/0008-5472.CAN-20-1453 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Expression and Role of p16 and GLUT1 in Malignant Diseases and Lung Cancer: A Review

Non‐small cell lung cancer (NSCLC) is the leading cause of cancer death and in most cases it is often diagnosed at an advanced stage. Many genetic and microenvironmental factors are able to modify the cell cycle inducing carcinogenesis and tumor growth.
[Thoracic Cancer]
Pezzuto, A., D’Ascanio, M., Ricci, A., Pagliuca, A., & Carico, E. (n.d.). Expression and role of p16 and GLUT1 in malignant diseases and lung cancer: A review. Thoracic Cancer, n/a(n/a). https://doi.org/10.1111/1759-7714.13651 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Silencing of lncRNA LINC00857 Enhances BIRC5-Dependent Radio-Sensitivity of Lung Adenocarcinoma Cells by Recruiting NFκB1

The authors identified a long noncoding RNA LINC00857 that might regulate radio-sensitivity of lung adenocarcinoma cells.
[Molecular Therapy-Nucleic Acids]
Han, F., Yang, S., Wang, W., Huang, X., Huang, D., & Chen, S. (2020). Silencing of lncRNA LINC00857 enhances BIRC5-dependent radio-sensitivity of lung adenocarcinoma cells by recruiting NFκB1. Molecular Therapy - Nucleic Acids, 0(0). https://doi.org/10.1016/j.omtn.2020.09.020 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Janssen Presents Findings from Global, Multi-Center Trial Examining Amivantamab in Combination with Lazertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer

The Janssen Pharmaceutical Companies of Johnson & Johnson announced interim results from the CHRYSALIS study, evaluating amivantamab, a fully human bispecific antibody that targets epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor mutations, in combination with the third-generation EGFR tyrosine kinase inhibitor lazertinib in patients with non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations.
[Janssen Global Services, LLC]
Press Release
Bookmark

No account yet? Register

0
Share

CB11, a Novel Purine-Based PPARɣ Ligand, Overcomes Radio-Resistance by Regulating ATM Signaling and EMT in Human Non-Small-Cell Lung Cancer Cells

CB11 caused cell death via reactive oxygen species-mediated ATM-p53-GADD45α signaling in human non-small-cell lung cancer cells, and diphenyleneiodonium, an NADPH oxidase inhibitor, decreases cell death by inhibiting CB11-mediated ATM signaling.
[British Journal of Cancer]
Abstract
Bookmark

No account yet? Register

0
Share

miR-196b-5p-Mediated Downregulation of FAS Promotes NSCLC Progression by Activating IL6-STAT3 Signaling

Investigators found that miR-196b-5p promoted lung cancer cell proliferation and colony formation by directly targeting tumor suppressor, FAS.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share

microRNA-130b-3p Contained in Mesenchymal Stem Cell-Derived Extracellular Vesicles Promotes Lung Cancer Progression by Regulating the FOXO3/NFE2L2/TXNRD1 Axis

A tumor xenograft mouse model was used to determine role of extracellular vesicles-microRNA-130b-3p and its target FOXO3 in lung cancer progression in vivo.
[Molecular Therapy-Oncolytics]
Guo, Q., Yan, J., Song, T., Zhong, C., Kuang, J., Mo, Y., Tan, J., Li, D., Sui, Z., Cai, K., & Zhang, J. (2020). microRNA-130b-3p Contained in Mesenchymal Stem Cell-Derived Extracellular Vesicles Promotes Lung Cancer Progression by Regulating the FOXO3/NFE2L2/TXNRD1 Axis. Molecular Therapy - Oncolytics, 0(0). https://doi.org/10.1016/j.omto.2020.09.005 Cite
AbstractFull ArticleGraphical Abstract
Bookmark

No account yet? Register

0
Share

Ruthenium (II) Complex cis-[RuII2-O2CC7H7O2)(dppm)2]PF6-hmxbato Induces ROS-Mediated Apoptosis in Lung Tumor Cells Producing Selective Cytotoxicity

Scientists analyzed the anticancer potential of hmxbato against lung tumor cells, as well as the partial death mechanisms involved.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

0
Share

miR-34c-3p Targets CDK1 a Synthetic Lethality Partner of KRAS in Non-Small Cell Lung Cancer

In vitro assays on immortalized and patient-derived primary non-small cell lung cancer cells revealed that miR-34c-3p overexpression increased apoptosis and lowered proliferation rate in KRASmut cells.
[Cancer Gene Therapy]
Full Article
Bookmark

No account yet? Register

0
Share
Share